Skip to main content
SpringerLink
Log in

Neoadjuvant Therapy for Pancreatic Cancer

  • review article
  • Published:
Journal of Gastrointestinal Surgery Aims and scope

Abstract

Surgical resection is necessary but generally insufficient as curative treatment for pancreatic cancer. Traditionally, postoperative (adjuvant) therapies have been utilized in an attempt to improve outcome, yet these efforts have met with extremely limited success. As preoperative (neoadjuvant) treatment strategies have evolved for the treatment of other malignancies, preoperative therapy for pancreatic cancer has been investigated by several groups over the past decade. At this time, no randomized trials comparing adjuvant and neoadjuvant therapies have been performed, nor have there been any large multicenter trials of neoadjuvant therapy for pancreatic cancer. In this manuscript, the rationale for neoadjuvant strategies are discussed in the context of the available data on both adjuvant and neoadjuvant therapy and clinical trials currently in development.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Jemal A. Cancer statistics, 2007. CA Cancer J Clin 2007;57:43–66.

    Article  PubMed  Google Scholar 

  2. Moertel CG, Frytak S, Hahn RG, Siegel R, Ward E, O’Connell MJ, Reitemeier RJ, Rubin J, Schutt AJ, Weiland LH, Childs DS, Holbrook MA, Lavin PT, Livstone E, Spiro H, Knwolton A, Kalser M, Barkin J, Lesssner H, Mann-Kaplan R, Ramming K, Douglas HO, Thomas P, Nave H, Bateman J, Lokich J, Brooks J, Chaffey J, Corson JM, Zamcheck N, Novak JW. Therapy of locally unresectable pancreatic carcinoma: A randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads +5-fluorouracil), and high dose radiation +5-fluorouracil: The Gastrointestinal Tumor Study Group. Cancer 1981;48:1705–1710.

    Article  PubMed  CAS  Google Scholar 

  3. Kalser MH, Ellenberg SS. Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection. Arch Surg 1985;120:899–903.

    PubMed  CAS  Google Scholar 

  4. Yeo CJ, Abrams RA, Grochow LB, Sohn TA, Ord SE, Hruban RH, Zahurak ML, Dooley WC, Coleman J, Sauter PK, Pitt HA, Lillemoe KD, Cameron JL. Pancreaticoduodenectomy for pancreatic adenocarcinoma: Postoperative adjuvant chemoradiation improves survival. A prospective, single-institution experience. Ann Surg 1997;225:621–633.

    Article  PubMed  CAS  Google Scholar 

  5. Klinkenbijl JH, Jeekel J, Sahmoud T, van Pel R, Couvreur ML, Veenhof CH, Arnaud JP, Gonzalez DG, de Wit LT, Hennipman A, Wils J. Adjuvant radiotherapy and 5 fluorouracil after curative resection of cancer of the pancreas and periampullary region: Phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann Surg 1999;230:776–782.

    Article  PubMed  CAS  Google Scholar 

  6. Neoptolemos JP, Stocken DD, Friess H, Bassi C, Dunn JA, Hickey H, Beger H, Fernandez-Cruz L, Dervenis C, Lacaine F, Falconi M, Pederzoli P, Pap A, Spooner D, Kerr DJ, Büchler MW, European Study Group for Pancreatic Cancer. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 2004;350:1200–1210.

    Article  PubMed  CAS  Google Scholar 

  7. Oettle H, Post S, Neuhaus P, Gellert K, Langrehr J, Ridwelski K, Schramm H, Fahlke J, Zuelke C, Burkart C, Gutberlet K, Kettner E, Schmalenberg H, Weigang-Koehler K, Bechstein WO, Niedergethmann M, Schmidt-Wolf I, Roll L, Doerken B, Riess H. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: A randomized controlled trial. JAMA 2007;297:267–277.

    Article  PubMed  CAS  Google Scholar 

  8. Regine WF, Winter KW, Abrams R. RTOG 9704, a phase III study of adjuvant pre and post chemoradiation (CRT) 5-FU vs. Gemcitabine for resected pancreatic adenocarcinoma (abstract 407). J Clin Oncol 2006;24:180s.

    Google Scholar 

  9. Bilimoria KY, Bentrem DJ, Ko CY, Tomlinson JS, Stewart AK, Winchester DP, Talamonti MS. Multimodality therapy for pancreatic cancer in the U.S.: Utilization, outcomes, and the effect of hospital volume. Cancer 2007;110:1227–1234.

    Article  PubMed  Google Scholar 

  10. Yeung RS, Weese JL, Hoffman JP, Solin LJ, Paul AR, Engstrom PF, Litwin S, Kowalyshyn MJ, Eisenberg BL. Neoadjuvant chemoradiation in pancreatic and duodenal carcinoma. A Phase II Study. Cancer 1993;72:2124–2133.

    Article  PubMed  CAS  Google Scholar 

  11. Staley CA, Lee JE, Cleary KA, Abbruzzese JL, Fenoglio CJ, Rich TA, Evans DB. Preoperative chemoradiation, pancreaticoduodenectomy, and intraoperative radiation therapy for adenocarcinoma of the pancreatic head. Am J Surg 1996;171:118–124.

    Article  PubMed  CAS  Google Scholar 

  12. Spitz FR, Abbruzzese JL, Lee JE, Pisters PW, Lowy AM, Fenoglio CJ, Cleary KR, Janjan NA, Goswitz MS, Rich TA, Evans DB. Preoperative and postoperative chemoradiation strategies in patients treated with pancreaticoduodenectomy for adenocarcinoma of the pancreas. J Clin Oncol 1997;15:928–937.

    PubMed  CAS  Google Scholar 

  13. White R, Hurwitz H, Lee C, Morse M, Anscher M, Paulson E, Gotfried M, Baillie J, Branch M, Jowell P, McGrath K, Clary B, Pappas T, Tyler DS. Neoadjuvant chemoradiation for localized adenocarcinoma of the pancreas. Ann Surg Oncol 2001;8:758–765.

    Article  PubMed  CAS  Google Scholar 

  14. Pisters PW, Wolff RA, Janjan NA, Cleary KR, Charnsangavej C, Crane CN, Lenzi R, Vauthey JN, Lee JE, Abbruzzese JL, Evans DB. Preoperative paclitaxel and concurrent rapid-fractionation radiation for resectable pancreatic adenocarcinoma: toxicities, histologic response rates, and event-free outcome. J Clin Oncol 2002;20:2537.

    Article  PubMed  CAS  Google Scholar 

  15. Wolff RA, Evans DB, Crane CH. Initial results of preoperative gemcitabine-based chemoradiation for resectable pancreatic adenocarcinoma (abstract). Proc Am Soc Clin Oncol 2002;21:130.

    Google Scholar 

  16. Talamonti MS, Small W Jr, Mulcahy MF, Wayne JD, Attaluri V, Colletti LM, Zalupski MM, Hoffman JP, Freedman GM, Kinsella TJ, Philip PA, McGinn CJ. A multi-institutional phase II trial of preoperative full-dose gemcitabine and concurrent radiation for patients with potentially resectable pancreatic carcinoma. Ann Surg Oncol 2006;13:150–158.

    Article  PubMed  Google Scholar 

  17. National Comprehensive Cancer Network (NCCN) Practice Guidelines for Pancreatic Cancer. http://www.nccn.org 2004.

  18. Varadhachary GR, Tamm EP, Abbruzzese JL, Xiong HQ, Crane CH, Wang H, Lee JE, Pisters PW, Evans DB, Wolff RA. Ann Surg Oncol 2006;13:1035–1046.

    Article  PubMed  Google Scholar 

  19. Snady H, Bruckner H, Cooperman A, Paradiso J, Kiefer L. Survival advantage of combined chemoradiotherapy compared with resection as the initial treatment of patients with regional pancreatic carcinoma. An outcomes trial. Cancer 2000;89:314–27.

    Article  PubMed  CAS  Google Scholar 

  20. Kim HJ, Czischke K, Brennan MF, Conlon KC. Does neoadjuvant chemoradiation downstage locally advanced pancreatic cancer. J Gastrointest Surg 2002;6:763–769.

    Article  PubMed  Google Scholar 

  21. White RR, Tyler DS. Neoadjuvant therapy for pancreatic cancer: The Duke experience. Surg Oncol Clin N Am 2004;13:675–684.

    Article  PubMed  Google Scholar 

  22. Isacoff WH, Bendetti JK, Barstis JJ, Jazieh AR, Macdonald JS, Philip PA. Phase II trial of infusional fluorouracil, leucovorin, mitomycin, and dipyridamole in locally advanced unresectable pancreatic adenocarcinoma: SWOG S9700. J Clin Oncol 2007;25:1665–1669.

    Article  PubMed  CAS  Google Scholar 

  23. Pipas JM, Barth RJ Jr, Zaki B, Tsapakos MJ, Suriawinata AA, Bettmann MA, Cates JM, Ripple GH, Sutton JE, Gordon SR, McDonnell CE, Perez RP, Redfield N, Meyer LP, Marshall JF, Cole BF, Colacchio TA. Docetaxel/Gemcitabine followed by gemcitabine and external beam radiotherapy in patients with pancreatic adenocarcinoma. Ann Surg Oncol 2005;12:995–1004.

    Article  PubMed  Google Scholar 

  24. Massucco P, Capussotti L, Magnino A, Sperti E, Gatti M, Muratore A, Sgotto E, Gabriele P, Aglietta M. Pancreatic resections after chemoradiotherapy for locally advanced ductal adenocarcinoma: Analysis of perioperative outcome and survival. Ann Surg Oncol. 2006;13:1201–1208.

    Article  PubMed  Google Scholar 

  25. Brunner TB, Grabenbauer GG, Meyer T, Golcher H, Sauer R, Hohenberger W. Primary resection versus neoadjuvant chemoradiation followed by resection for locally resectable or potentially resectable pancreatic carcinoma without distant metastasis. A multi-centre prospectively randomised phase II-study of the Interdisciplinary Working Group Gastrointestinal Tumours (AIO, ARO, and CAO). BMC Cancer 2007;6:41–45.

    Article  Google Scholar 

  26. Crane CH, Ellis LM, Abbruzzese JL, Amos C, Xiong HQ, Ho L, Evans DB, Tamm EP, Ng C, Pisters PW, Charnsangavej C, Delclos ME, O'Reilly M, Lee JE, Wolff RA. Phase I trial evaluating the safety of bevacizumab with concurrent radiotherapy and capecitabine in locally advanced pancreatic cancer. J Clin Oncol. 2006;24:1145–1151.

    Article  PubMed  CAS  Google Scholar 

  27. Duffy A, Kortmansky J, Schwartz GK, Capanu M, Puleio S, Minsky B, Saltz L, Kelsen DP, O'reilly EM. A phase I study of erlotinib in combination with gemcitabine and radiation in locally advanced, non-operable pancreatic adenocarcinoma. Ann Oncol 2008;19:86–91.

    Article  PubMed  CAS  Google Scholar 

  28. White R, Xie B, Gotfried M, Hurwitz H, Morse M, Blobe G, Czito B, Paulson E, Baillie J, Branch M, Jowell P, Clary B, Pappas T, Tyler DS. Prognostic significance of histologic response to preoperative chemoradiation of periampullary malignancies. Ann Surg Oncol. 2005;12:214–221.

    Article  PubMed  Google Scholar 

  29. Hoffman JP, Lipsitz S, Pisansky T, Weese JL, Solin L, Benson AB 3rd. Phase II trial of preoperative radiation therapy and chemotherapy for patients with localized, resectable adenocarcinoma of the pancreas: An Eastern Cooperative Oncology Group Study. J Clin Oncol 1998;16:317–323.

    PubMed  CAS  Google Scholar 

  30. Pisters PW, Abbruzzese JL, Janjan NA, Cleary KR, Charnsangavej C, Goswitz MS, Rich TA, Raijman I, Wolff RA, Lenzi R, Lee JE, Evans DB. Rapid-fractionation preoperative chemoradiation, pancreaticoduodenectomy, and intraoperative radiation therapy for resectable pancreatic adenocarcinoma. J Clin Oncol 1998;16:3843.

    PubMed  CAS  Google Scholar 

  31. Meszoely IM, Wang H, Hoffman JP. Preoperative chemoradiation therapy for adenocarcinoma of the pancreas: The Fox Chase Cancer Center experience, 1986–2003. Surg Oncol Clin N Am 2004;13:685–696.

    Article  PubMed  Google Scholar 

  32. Moutardier V, Magnin V, Turrini O, Viret F, Hennekinne-Mucci S, Gonçalves A, Pesenti C, Guiramand J, Lelong B, Giovannini M, Monges G, Houvenaeghel G, Delpero JR. Assessment of pathologic response after preoperative chemoradiotherapy and surgery in pancreatic adenocarcinoma. Int J Radiat Oncol Biol Phys 2004;60:437.

    PubMed  Google Scholar 

  33. Mornex F, Girard N, Delpero JR, Partensky C. Radiochemotherapy in the management of pancreatic cancer—Part I: neoadjuvant treatment. Semin Radiat Oncol 2005;15:226–234.

    Article  PubMed  Google Scholar 

  34. Kamthan AG, Morris JC, Dalton J, Mandeli JP, Chesser MR, Leben D, Cooperman A, Bruckner HW. Combined modality therapy for stage II and stage III pancreatic carcinoma. J Clin Oncol 1997;15:2920–2927.

    PubMed  CAS  Google Scholar 

  35. Ammori JB, Colletti LM, Zalupski MM, Eckhauser FE, Greenson JK, Dimick J, Lawrence TS, McGinn CJ. Surgical resection following radiation therapy with concurrent gemcitabine in patients with previously unresectable adenocarcinoma of the pancreas. J Gastrointest Surg 2003;7:766–772.

    Article  PubMed  Google Scholar 

  36. Aristu J, Canon R, Pardo F, Martínez-Monge R, Martin-Algarra S, Manuel Ordoñez J, Villafranca E, Moreno M, Cambeiro M, Azinovic I. Surgical resection after preoperative chemoradiotherapy benefits selected patients with unresectable pancreatic cancer. Am J Clin Oncol 2003;26:30–36.

    Article  PubMed  Google Scholar 

  37. Joensuu TK, Kiviluoto T, Kärkkäinen P, Vento P, Kivisaari L, Tenhunen M, Westberg R, Elomaa I. Phase I–II trial of twice-weekly gemcitabine and concomitant irradiation in patients undergoing pancreaticoduodenectomy with extended lymphadenectomy for locally advanced pancreatic cancer. Rad Oncol 2004;60:444–452.

    CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Surgery, University of California, San Diego, 3855 Health Sciences Drive, La Jolla, CA, 92093-0987, USA

    Andrew M. Lowy

Authors
  1. Andrew M. Lowy
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Andrew M. Lowy.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lowy, A.M. Neoadjuvant Therapy for Pancreatic Cancer. J Gastrointest Surg 12, 1600–1608 (2008). https://doi.org/10.1007/s11605-008-0482-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11605-008-0482-2

Keywords

Search

Navigation